Anteris Technologies, a pioneering structural heart company headquartered in Brisbane, Australia, and Minneapolis, USA, has unveiled groundbreaking advancements in transcatheter heart valves with their DurAVR™ THV. This innovative device, crafted from a single-piece biomimetic design, mirrors the intricate functionality of the human aortic valve. Recently showcased at the prestigious New York Valves 2024 Conference, Anteris presented compelling data from their DurAVR™ THV valve-in-valve (ViV) procedures.
Dr. Anita Asgar of Institut de Cardiologie de Montreal highlighted the outcomes of ViV procedures using DurAVR™ THV in five high-risk patients. These cases, facilitated under Health Canada’s special access program, underscored the efficacy of DurAVR™ in restoring patients' hemodynamics akin to their initial surgical valve performance. This achievement marks a significant stride forward, particularly for patients requiring secondary valve replacements due to bioprosthetic valve deterioration.
The ViV approach, a less invasive alternative to reoperative surgical procedures, addresses unique challenges inherent to such interventions. Dr. Asgar emphasized the complexity of decision-making in these cases, noting the operational intricacies involved in ensuring optimal valve function and coronary artery accessibility. Traditional TAVR devices often pose limitations in hemodynamic performance for severely ill patients, further highlighting the critical role of advanced technologies like DurAVR™ THV.
Anteris' clinical data demonstrated a remarkable reduction in aortic valve gradients post-DurAVR™ ViV implantation, with echo data revealing gradients comparable to those post-initial surgical replacement. The average gradient decrease from pre-ViV levels underscores the therapeutic potential of DurAVR™ in enhancing patient outcomes without major complications reported during the study period.
Founded on a foundation of innovation and driven by a multidisciplinary team of experts, Anteris Technologies continues to push the boundaries in structural heart disease management. Their ADAPT® tissue technology, integrated into DurAVR™ THV, has been pivotal in mitigating calcification risks, benefiting over 55,000 patients globally. The proprietary ComASUR™ Delivery System ensures precise deployment, optimizing valve positioning within the native anatomy for superior clinical efficacy.
Anteris Technologies' commitment to scientific rigor and transformative medical solutions positions them at the forefront of the structural heart market. With DurAVR™ THV setting new benchmarks in valve-in-valve procedures, the company remains dedicated to addressing significant unmet clinical needs and improving the quality of life for patients worldwide. As they continue to innovate, Anteris Technologies reaffirms its mission to redefine standards in cardiovascular care through cutting-edge technologies and clinical excellence.
